Vaxxas, a start-up vaccine technology company owned by the University of Queensland’s commercialisation arm UniQuest, has received a further $25 million in funding to continue developing the Nanopatch, a painless vaccine delivery system.
Invented by Professor Mark Kendall of the Australian Institute for Bioengineering and Nanotechnology, the Nanopatch, which is about the size of a postage stamp, is designed to replace the dreaded needle with a new, painless method of vaccination.
The funding brings the technology closer to being clinically proven, and enables it to be applied to a wider range of vaccines for various major diseases.
The Nanopatch, which works by distributing the vaccine via thousands of tiny projections to immune cells in the skin, is cheaper, easy to transport and to access than needles, which has particularly important implications for developing nations.
Fantastic and practical research such as this demonstrates the importance of supporting the wonderful innovation coming out of Australian universities every day.
Professor Mark Kendall about Vaxxas Nanopatch at Technology Pioneer 2015 via World Economic Forum
Professor Mark Kendall demo on TED Talks [uploaded Jan 2014]
[img source] The Conversation bit.ly/1ACTkNq